The future of cardiac care was on display at the Heart Rhythm Society’s 2023 annual meeting. Medical device companies showcased groundbreaking technologies at Heart Rhythm 2023, May 19-21 in New Orleans. The innovations presented during the event offer new avenues for diagnosis, treatment, and monitoring of cardiovascular conditions, providing hope for patients worldwide. Boston Scientific, […]
HRS 2023
Philips study shows AI can help predict ventricular tachycardia
Philips (NYSE:PHG) presented data demonstrating how artificial intelligence (AI) can help predict life-threatening ventricular arrhythmias. Amsterdam-based Philips presented an abstract highlighting recent research at the annual Hearth Rhythm Society (HRS) congress in New Orleans. The study, “Near-Term Prediction of Life-Threatening Ventricular Arrhythmias using Artificial Intelligence-Enabled Single Lead Ambulatory ECG,” used an AI-based learning model. It […]
Study supports extravascular ICD from Medtronic
Medtronic (NYSE:MDT) announced positive long-term follow-up results for its investigational implantable cardioverter defibrillator (ICD). The medtech giant designed its extravascular (EV) ICD system to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest. Medtronic’s EV ICD pivotal study followed patients through an average of 17.1 months. The company presented data as late-breaking […]
New data from iRhythm back the use of long-term ambulatory cardiac monitoring
iRhythm (Nasdaq:IRTC) today announced the presentation of four studies reinforcing evidence behind its long-term cardiac monitoring. San Francisco-based iRhythm presented the data at the Heart Rhythm Society’s annual meeting, Heart Rhythm 2023, in New Orleans. Data supports ambulatory cardiac monitoring of up to 14 days with the company’s Zio XT. It demonstrated increased diagnostic yield […]
Data backs Abbott Aveir dual-chamber leadless pacemaker
Abbott (NYSE:ABT) today announced late-breaking results from a study of its Aveir dual-chamber (DR) i2i leadless pacemaker. The data came from the company’s large-scale FDA investigational device exemption (IDE) study. It assesses Aveir DR, the world’s first dual-chamber leadless pacemaker for safety and performance. Abbott said the data suggests that Aveir DR could offer new […]
Medtronic reports positive study results for PulseSelect pulsed-field ablation system
Medtronic (NYSE:MDT) today announced positive findings from a secondary analysis of the PULSED AF study for its pulsed-field ablation technology. The analysis demonstrated positive results for the PulseSelect system, including atrial arrhythmia (AA) burden reduction. This correlated to both improved quality of life and decreased healthcare utilization. Medtronic said in a news release that 87% […]